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exercise the blood pressure cuff was deflated to reestab-
lish circulation. The results of two subjects are shown in
Table 1. Both are normal responses in that the basal lactate
was ,2 mmol/L and that this was followed by an
increase to .2.5 mmol/L in the first 4–5 min post
exercise, the peak being between 1 and 3 min.
The ischemic exercise test is not a frequently performed
test, and the procedure for it is not described in easily
available clinical chemistry textbooks, e.g., Tietz Textbook
of Clinical Chemistry (1999) and Kaplan and Pesce’s Clinical
Chemistry (1989), or in The Metabolic and Molecular Bases of
Inherited Disease (1 ). This makes it all the more important
to emphasize that to avoid false-positive results and
unnecessary traumatic repetitions of the test, the blood
pressure cuff must be deflated before the postexercise
specimens are taken.
Since performing this study, we have discovered that
the procedure for the ischemic exercise test is correctly
described by Thomas (3 ). However, his prescription of
ischemic exercise for 2 min (rather than 1 min) can be
difficult for many people and appears to be unnecessary.
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The enzyme catalase (EC 1.11.1.6) has a predominant role
in controlling the concentration of hydrogen peroxide in
human erythrocytes (1 ). Hydrogen peroxide is involved
in physiological processes, but its increased concentration
may contribute to the pathogenesis of various diseases,
such as diabetes and atherosclerosis. Human erythrocytes
with high catalase content provide a general defense
against toxic concentrations of hydrogen peroxide (2, 3).
Hypocatalasemia is the heterozygous state of the acata-
lasemia gene and is inherited as an autosomal, recessive
trait without any characteristic clinical sign. The fre-
quency of hypocatalasemia in East Asia is 0.2–0.4%,
whereas in two Iranian populations it is 0.5% (4, 5). There
are only limited data available on the disease-causing
mutations. The splicing mutation (guanine-to-adenine
substitution) at the fifth position of intron 4 and the 358T
deletion in exon 4 have been detected in five Japanese
patients (6–8).
We have reported on nine hypocatalasemic families for
the first time in Hungary (9 ). The frequency of inherited
hypocatalasemia is 0.18% in Hungary (9 ). The syndrome-
causing mutations detected in Japanese patients (6–8)
have not been found in the Hungarian hypocatalasemic
patients (10, 11).
We report here on a new catalase mutation that caused
hypocatalasemia in three (M, D, and G) Hungarian hy-
pocatalasemic families. For this mutation, we amplified
all exons and exon-intron junctions of the catalase gene by
PCR. These PCR products were screened for mutations by
a simple heteroduplex detection method. The mutation
was determined by nucleotide sequence analysis.
Genomic DNA was isolated from 23 hypocatalasemic
and 25 normocatalasemic members of six Hungarian
hypocatalasemic families. The DNA extraction was made
by a QIAamp Blood Kit (QIAGEN). The PCR amplifica-
tion was performed in a total volume of 10.5 mL, contain-
ing 1 mL of genomic DNA (0.2 mg/mL), 1.6 mL of four
dNTPs (1.25 mmol/L each), 1 mL of each primer (10
mmol/L), 0.5 mL of 5 U/mL Taq polymerase, 1 mL of 8.3
mmol/L MgCl2, and 1 mL of buffer. PCR reagents were
purchased from Pharmacia. Thirty cycles of amplification
at 94, 55, and 72 °C for 0.5, 0.5, and 1 min, respectively,
were performed in a DNA thermal cycler (TC 1; Perkin-
Elmer Cetus). Oligonucleotide primers were synthesized
by Pharmacia, according to the sequences reported by
Kishimoto et al. (7 ).
Heteroduplex analysis was performed according to the
Hydrolink protocol (AT Biochem). PCR product (2 mL)
was heated to 94 °C, cooled down slowly, and then loaded
onto a Hydrolink gel (280 3 180 3 0.75 mm). DNA bands
Fig. 1. Pedigree (top), heteroduplex pattern (middle), and nucleotide
sequence analysis (bottom) of hypocatalasemic family G.
(Top), , hypocatalasemic female; m, hypocatalasemic male; M, normocata-
lasemic male. (Middle), the heteroduplex pattern A represents a wild-wild
homoduplex, B represents a mutant-mutant homoduplex, and C and D represent
wild-mutant heteroduplexes. (Bottom), the nucleotide sequence analyses show
nucleotides 127–138 for the wild type and 127–140 for the mutant. The GA
repeats are numbered above the nucleotide sequence.
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on the polyacrylamide gel were visualized by silver
staining (Bio-Rad). PCR products were purified by poly-
acrylamide gel electrophoresis and used for sequence
analyses. The sequencing reactions were carried out using
the Taq Dye-Deoxy Termination Cycle Sequencing Kit
and DNA Sequencer (Model 373) from Applied Biosys-
tems.
The mutation screening showed heteroduplex forma-
tion only for exon 2. These heteroduplexes were detect-
able for every hypocatalasemic (n 5 23) but not for the
normocatalasemic (n 5 26) members of families M, D, and
G. No heteroduplex formation was detected in the hy-
pocatalasemic and normocatalasemic members of the
other three hypocatalasemic families.
The heteroduplex pattern showed the first band at 268
bp (wild-wild homoduplex), the second at ;270 bp (mu-
tant-mutant homoduplex), and two heteroduplexes at 273
and 304 bp. It is rare to be able to distinguish these four
bands so clearly. Separation of the patterns of the four
bands in exon 2 were found in the same well when a
smaller gel (150 3 150 3 1.5 mm) was prepared with
molecular biology-grade polyacrylamide (Bio-Rad) and
no sample treatment was used (Fig. 1, middle panel).
The nucleotide sequence analysis showed a GA inser-
tion (Fig. 1, bottom panel) at position 138 of exon 2. This
insertion increased the GA repeat number from four to
five and caused a frameshift mutation. This frameshift
changed the amino acid sequence from position 68 and
generated a terminating codon of TGA at position 134.
The mutation yielded a truncated protein and the lack of
histidine 74, which is required for the binding of a
hydrogen peroxide substrate (12 ). These findings could
explain the decreased blood catalase activities of the
hypocatalasemic patients (49.2 6 13.7 MU/L; n 5 23)
compared with the normocatalasemic family members
(107.6 6 19.5 MU/L; n 5 26). The heteroduplex formed
from a 268-bp wild-type and a 270-bp mutant PCR
product required neither pretreatment nor a special gel
for its detection. This simple method was checked when
the screening of the 625 normocatalasemic subjects
yielded no heteroduplex formation.
In conclusion, a simple heteroduplex analysis of PCR
products could be used for screening of GA insertions in
exon 2 of the catalase gene. This new syndrome-causing
mutation was detected in three of the nine hypocata-
lasemic families in Hungary. These data confirm the
heterogeneity of the acatalasemia/hypocatalasemia de-
tected in Hungary.
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The determination of bone metabolism markers is useful
in monitoring pharmacological therapy for osteoporosis
(1–3). During the course of multicenter clinical studies
designed to evaluate the therapeutic efficacy of several
drugs, it often is useful to carry out analysis in batches
after storing the samples for differing periods, thus reduc-
ing analytical variation and cost. This requires knowledge
of the behavior of the analyte in the biological matrix in
terms of the length and conditions of storage. Unfortu-
nately, these data frequently are lacking, and the informa-
tion provided by a kit’s manufacturer more often than not
is contradictory.
Data published relative to long-term storage in biolog-
ical matrices of bone turnover markers, including the seric
NH2-terminal propeptide of type I procollagen (P1NP),
the urinary cross-linked N-telopeptides of type I collagen
(NTx), and the urinary pyridinium cross-links pyridino-
line (PYD) and deoxypyridinoline (DPD), are extremely
scarce (4 ). Therefore, our aim was to systematically study
the molecular stability of these analytes in the storage
mode most frequently used. In particular, the stability of
storage lengths from 1 day to 12 months at temperatures
between 280 °C and 23–25 °C were studied.
The biological samples were collected from 10 healthy
subjects, 7 females and 3 males, between 25 and 64 years
of age (mean 6 SD, 36.1 6 13.2 years), who had fasted
from midnight. The venous blood samples were collected
between 0800 and 0900, and the serum was separated
through centrifugation, divided into 1-mL aliquots in
micro test tubes, and stored at 23–25, 2–8, 220, or 280 °C.
At the same time, aliquots of the second urine (fasting) of
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